Summary
Steroid receptor levels and serum androgen levels were determined in 61 breast cancer patients and 34 patients with non-malignant breast lesions. Testosterone and dehydroepiandrosterone-sulfate did not and androstenedione did show a difference between the two groups. Androgen levels had no influence on survival rates. Androgen receptor (AR) levels correlated with progesterone receptor levels, but not with estrogen receptor levels or with tumor stage. Patients with positive AR findings had a better survival rate; this was independent of tumor stage. AR findings may therefore be a prognostic index in breast cancer patients.
Similar content being viewed by others
References
Allegra JC, Lippman ME, Thompson EB et al. (1979) Distribution, frequency, and quantitative analysis of estrogen, progesterone, androgen, and glucocorticoid receptors in human breast cancer. Cancer Res 39:1447–1451
Bezwoda WR, Mansoor N, Dansey R, Esser JD (1987) Aromatisation of androstenedione by human breast cancer tissue: Correlation with hormone receptor activity and possible biologic significance. Oncology 44:30–33
Bonadonna G, Brusamolino E, Valagussa P (1976) Combination chemotherapy as an adjuvant treatment in operable cancer. N Engl J Med 294:405
Brentani MM, Franco EL, Oshima CT, Pacheco MM (1986) Androgen, estrogen, and progesterone receptor levels in malignant and benign breast tumors: a multivariate analysis approach. Int J Cancer 36:639–642
Bryan RM, Mercer RJ, Bennett RC, Rennie GC, Lie TH, Morgan FJ (1984) Oestradiol receptor values in breast cancer and response of metastases to therapy. Aust NZ J Surg 54:3–6
Bryan RM, Mercer RJ, Bennett RC, Rennie GC, Lie TH, Morgan FJ (1984) Androgen receptors in breast cancer. Cancer 54:2436–2440
Cox DR (1972) Regression models and life tables. J Roy Statist Soc 34:187–220
Cuzcik J (1982) Rank tests for association with right censored data. Biometrika 69:351–364
Dixon WJ (ed) (1987) BMDP Biomedical computer programs. University of California Press, Berkeley
Grill HJ, Manz B, Belovsky O, Pollow K (1984) Criteria for the establishment of a double-lab assay for simultanous determination of estrogen and progesterone receptors. Oncology 41:25–32
Grill HJ, Moebius U, Manz B, Pollow K (1983) Determination of androgen receptors. Steroid Biochem 19:1687
Henderson JC, Mouridsen H, Breast Cancer Collaborative Group (1988) Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. N Engl J Med 319:1681–1692
Horn H, Gordan GS (1974) Plasma testosterone in advanced breast cancer. Oncology 30:147–151
Lippmann, ME (1980) Steroid receptor analyses and endocrine therapy of breast cancer. In: Bresciani F (ed) Perspectives in steroid receptor research. Raven Press, New York
Malarkey WB, Schroeder LL, Stevens VC, James AG, Lanese RR (1977) Twenty-four-hour preoperative endocrine profiles in women with benign and malignant breast disease. Cancer Res 37:4655–4659
McGuire WL (1978) Hormone receptors: their role in predicting prognosis and response to endocrine therapy. Semin Oncol 5:428–433
Miller WR, Telford J, Dixon JM, Hawkins RA (1985) Androgen receptor activity in human breast cancer and its relationship with oestrogen and progestogen receptor activity. Eur J Cancer Clin Oncol 21:539–544
Persijn JP, Korsten CB, Engelsman E (1975) Oestrogen and androgen receptors in breast cancer and response to endocrine therapy. Br Med J 4:503
Pollow K, Schweikhart G, Mitze M (1982) Verteilung von Östradiol-, Progesteron-, Androgen-und Glukokortikoidrezeptoren in Mammacarcinomen der Frau. In: Jonat W, Maass H (eds) Steroidhormonrezeptoren im Karzinomgewebe. Enke Verlag, Stuttgart
Reiner G, Bieglmayer Ch, Jakesz R, Kolb R, Spona J (1979) Estradiol and progesterone receptor levels in human breast carcinomas in relation to hormone serum levels in postmenopausal women. Cancer Treat Rep 63:1185
Reiner G, Jakesz R, Kolb R, Kühnl-Brady K, Reiner A, Schemper M, Spona J (1988) Androgenrezeptoren beim primären Mammakarzinom. Dtsch Med Wochenschr 113:892–897
Rose LI, Underwood RH, Dunning MT, Williams GH, Pinkus GS (1975) Testosterone metabolism in benign and malignant breast lesions. Cancer 36:399–403
Scatchard G (1949) The attraction of proteins for small molecules and ions. Ann NY Acad Sci 51:660
Secreto G, Fariselli G, Bandieramonte G, Recchione C, Dati V, DiPietro S (1983) Androgen excretion in women with a family history of breast cancer or with epithelial hyperplasia of the breast. Eur J Cancer Clin Oncol 19:5–10
Trams G, Maass H (1977) Specific binding of estradiol and dihydrotestosterone in human mammary cancers. Cancer Res 37:258
Wang DY, Moore JW, Thomas BS, Bulbrook RD, Hoare SA, Tong D, Hayward JL (1979) Plasma and urinary androgens in women with varying degrees of risk of breast cancer. Eur J Cancer 15:1269–1274
Zielinski Ch, Kuzmits R, Kubista E, Salzer H, Staffen A, Aiginger P, Spona J (1985) Die Bedeutung der Hormonrezeptoren von Mammakarzinomzellen für die Dauer des erkrankungsfreien Intervalls. Wi Kli Wochenschr 97/11:493–497
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Langer, M., Kubista, E., Schemper, M. et al. Androgen receptors, serum androgen levels and survival of breast cancer patients. Arch Gynecol Obstet 247, 203–209 (1990). https://doi.org/10.1007/BF02389545
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02389545